Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
暂无分享,去创建一个
Dhanunjaya R. Lakkireddy | M. Mansour | J. Ruskin | J. Burkhardt | A. Natale | V. Reddy | L. Di Biase | P. Mohanty | Javier E. Sanchez | A. d'Avila | P. Santangeli | L. Biase | D. Lakkireddy | G. Monir | Y. Reddy | N. Shaik | S. Vanga | Rhea C. Pimentel | F. Chalhoub | V. Swarup | J. Coffey | Fadi Chalhoub
[1] G. Hindricks,et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[2] David O. Martin,et al. Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation , 2013, Circulation. Arrhythmia and electrophysiology.
[3] G. Breithardt,et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.
[4] S. Kusachi,et al. Usefulness of Dabigatran Etexilate as Periprocedural Anticoagulation Therapy for Atrial Fibrillation Ablation , 2013, Clinical Drug Investigation.
[5] B. Knight,et al. Optimal Strategies Including Use of Newer Anticoagulants for Prevention of Stroke and Bleeding Complications Before, During, and After Catheter Ablation of Atrial Fibrillation and Atrial Flutter , 2013, Current Treatment Options in Cardiovascular Medicine.
[6] F. Morady,et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. , 2013, Heart rhythm.
[7] D. Garcia,et al. The Novel Oral Anticoagulants , 2013, Seminars in Thrombosis & Hemostasis.
[8] T. Murohara,et al. A Randomized Controlled Trial of Dabigatran versus Warfarin for Periablation Anticoagulation in Patients Undergoing Ablation of Atrial Fibrillation , 2013, Pacing and clinical electrophysiology : PACE.
[9] A. Natale,et al. How to ablate long-standing persistent atrial fibrillation? , 2012, Current opinion in cardiology.
[10] S. Oshima,et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[11] R. Winkle,et al. Safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation. , 2012, Journal of the American College of Cardiology.
[12] A. Pillai,et al. Rivaroxaban and its Effect on International Normalised Ratio-A Prospective Study of 28 Hip and Knee Arthroplasty Patients , 2012 .
[13] David Keane,et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[14] J. Burkhardt,et al. Ablation of Atrial Fibrillation Under Therapeutic Warfarin Reduces Periprocedural Complications: Evidence From a Meta-Analysis , 2012, Circulation. Arrhythmia and electrophysiology.
[15] R. Winkle,et al. The Use of Dabigatran Immediately After Atrial Fibrillation Ablation , 2012, Journal of cardiovascular electrophysiology.
[16] P. Kirchhof,et al. Bleeding risk assessment and management in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.
[17] P. Kamphuisen,et al. Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.
[18] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[19] K. Ylitalo,et al. Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[20] John Camm,et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[21] A. Natale,et al. Atrial Fibrillation Ablation without Interruption of Anticoagulation , 2011, Cardiology research and practice.
[22] G. Hankey,et al. Dabigatran Etexilate: A New Oral Thrombin Inhibitor , 2011, Circulation.
[23] Kenneth A Ellenbogen,et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.
[24] D. Mehta,et al. Thromboembolic Risk and Anticoagulation Strategies in Patients Undergoing Catheter Ablation for Atrial Fibrillation , 2011, Current cardiology reports.
[25] Kenneth A Ellenbogen,et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.
[26] E. Heist,et al. Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation , 2011, Journal of Interventional Cardiac Electrophysiology.
[27] Carlo Boffano,et al. Radiofrequency Catheter Ablation of Atrial Fibrillation: A Cause of Silent Thromboembolism?: Magnetic Resonance Imaging Assessment of Cerebral Thromboembolism in Patients Undergoing Ablation of Atrial Fibrillation , 2010, Circulation.
[28] E. Hylek,et al. New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs , 2010, Thrombosis and Haemostasis.
[29] Stacy A. Johnson,et al. Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. , 2010, Thrombosis research.
[30] Sanghamitra Mohanty,et al. Left Atrial Appendage: An Underrecognized Trigger Site of Atrial Fibrillation , 2010, Circulation.
[31] Dhanunjaya R. Lakkireddy,et al. Periprocedural Stroke and Management of Major Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The Impact of Periprocedural Therapeutic International Normalized Ratio , 2010, Circulation.
[32] S. Johnston,et al. Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States , 2010, Clinical cardiology.
[33] M. Feuring,et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.
[34] Elia Biganzoli,et al. Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.
[35] Thorsten Lewalter,et al. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[36] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[37] David O. Martin,et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. , 2009, Heart rhythm.
[38] Douglas Packer,et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. , 2009, Journal of the American College of Cardiology.
[39] Yuping Xiao,et al. Femoral vascular complications following catheter ablation of atrial fibrillation , 2009, Journal of Interventional Cardiac Electrophysiology.
[40] T. Kuwahara,et al. Complications in the catheter ablation of atrial fibrillation: incidence and management. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[41] A. Waldo. Complications of Catheter Ablation for Atrial Fibrillation: Incidence and Predictors , 2009 .
[42] Bengt I Eriksson,et al. Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement , 2008, Thrombosis and Haemostasis.
[43] W. Mueck,et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects , 2008 .
[44] J. Ruskin,et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.
[45] J. Sra. Atrial fibrillation ablation complications , 2008, Journal of Interventional Cardiac Electrophysiology.
[46] David O. Martin,et al. Atrial Fibrillation Ablation in Patients With Therapeutic International Normalized Ratio: Comparison of Strategies of Anticoagulation Management in the Periprocedural Period , 2007, Circulation.
[47] J. Ruskin,et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.
[48] F. Marchlinski,et al. How to recognize, manage, and prevent complications during atrial fibrillation ablation. , 2007, Heart rhythm.
[49] A. Natale,et al. How to do circular mapping catheter-guided pulmonary vein antrum isolation: the Cleveland Clinic approach. , 2006, Heart rhythm.
[50] Michael Becka,et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects , 2005, European Journal of Clinical Pharmacology.
[51] Atul Verma,et al. Pulmonary Vein Antrum Isolation: , 2004, Journal of cardiovascular electrophysiology.
[52] David O. Martin,et al. Impact of Age on the Outcome of Pulmonary Vein Isolation for Atrial Fibrillation Using Circular Mapping Technique and Cooled‐Tip Ablation Catheter: , 2004, Journal of cardiovascular electrophysiology.